S F L van Lelyveld
Overview
Explore the profile of S F L van Lelyveld including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
64
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Winkel A, Winkel A, Kozanli E, Kozanli E, Haverkort M, Haverkort M, et al.
J Infect Dis
. 2024 Nov;
PMID: 39510121
Background: Knowledge of SARS-CoV-2 household transmission dynamics guides infection control and vaccination measures. This household cohort study prospectively assessed the impact of both the Omicron BA.2 variant and immunity on...
2.
Aynekulu Mersha D, van der Sterren I, Leeuwen L, Langerak T, Hakim M, Martina B, et al.
Trop Dis Travel Med Vaccines
. 2024 Nov;
10(1):22.
PMID: 39482727
Dengue is the most rapidly spreading vector-borne disease worldwide, with over half the global population at risk for an infection. Antibody-dependent enhancement (ADE) is associated with increased disease severity and...
3.
Goeijenbier M, van der Bie S, Souverein D, Bolluyt D, Nagel M, Stoof S, et al.
J Clin Med
. 2024 Jun;
13(12).
PMID: 38929972
: () infections can progress to severe respiratory complications, necessitating intensive care treatment. Recent post COVID-19 pandemic surges underscore the need for timely diagnosis, given potential diagnostic method limitations. A...
4.
van Lelyveld S, Symons J, van Ham P, Connell B, Nijhuis M, Wensing A, et al.
Int J Antimicrob Agents
. 2015 Nov;
47(1):84-90.
PMID: 26585497
Available data on the use of maraviroc (MVC) in clinical settings are limited. In this cohort study, the clinical outcomes of HIV-1-infected patients treated with MVC were analysed and the...
5.
Krikke M, van Lelyveld S, Tesselaar K, Arends J, Hoepelman I, Visseren F
Atherosclerosis
. 2014 Sep;
237(1):92-8.
PMID: 25238214
Cardiovascular disease (CVD) is highly prevalent in HIV-infected patients. Besides the classical cardiovascular risk factors, HIV related factors play a role, such as immune activation and treatment with highly active...
6.
Symons J, Vandekerckhove L, Paredes R, Verhofstede C, Bellido R, Demecheleer E, et al.
Clin Microbiol Infect
. 2011 Sep;
18(6):606-12.
PMID: 21906210
Guidelines state that the CCR5-inhibitor Maraviroc should be prescribed to patients infected with R5-tropic HIV-1 only. Therefore, viral tropism needs to be assessed phenotypically or genotypically. Preliminary clinical trial data...
7.
van Lelyveld S, Wind C, Mudrikova T, van Leeuwen H, de Lange D, Hoepelman A
Eur J Clin Microbiol Infect Dis
. 2011 Feb;
30(9):1085-93.
PMID: 21331480
The purpose of this investigation was to analyse the impact of the availability of highly active antiretroviral therapy (HAART) on the long-term outcome of human immunodeficiency virus (HIV)-infected patients admitted...
8.
van Lelyveld S, Nijhuis M, Baatz F, Wilting I, van den Bergh W, Kurowski M, et al.
Clin Infect Dis
. 2010 Jan;
50(3):387-90.
PMID: 20047481
We report the selection of enfuvirtide-resistant human immunodeficiency virus type 1 in cerebrospinal fluid, resulting in subsequent loss of viral suppression in the plasma. This case report emphasizes the potential...